Matthew Pauls
Director at Pelthos Therapeutics Inc. (PTHS)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $54K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 6SEC | PTHSPelthos Therapeutics Inc. | Sell Plan | 78613,578 held (−5%) | $21.00 | $17K | -2.4% |
| Jul 7SEC | PTHSPelthos Therapeutics Inc. | Sell Plan | 69214,458 held (−5%) | $26.00 | $18K | -21.2% |
| Jul 7SEC | PTHSPelthos Therapeutics Inc. | Sell Plan | 9414,364 held (−1%) | $27.36 | $3K | -25.1% |
| Apr 6SEC | PTHSPelthos Therapeutics Inc. | Sell Plan | 41515,521 held (−3%) | $20.52 | $9K | -0.1% |
| Apr 6SEC | PTHSPelthos Therapeutics Inc. | Sell Plan | 37115,150 held (−2%) | $21.36 | $8K | -4.0% |
- Sell
Director Matthew Pauls sold $17K of PTHS at $21.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Matthew Pauls sold $18K of PTHS at $26.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Matthew Pauls sold $3K of PTHS at $27.36 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Matthew Pauls sold $9K of PTHS at $20.52 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Matthew Pauls sold $8K of PTHS at $21.36 — pre-scheduled 10b5-1 plan sale.